Why the 2026 Probiotic and Secretome Paper Reports No Trial Results Yet: Questions People With Acne-Prone Skin Can Ask a Dermatologist

The June 2026 paper reports no trial results because it is a trial protocol, not a finished study. BMJ Open published it on 4 June 2026 to describe methods and analysis for a future phase 2 study, as shown in the published trial protocol.

The planned study tests oral probiotics plus a topical secretome as add-ons to standard acne care. Secretome means a cell-free mixture of probiotic-derived metabolites and bioactive factors, not live bacteria. It is intended to affect skin microbes, calm inflammation, and limit harmful colonization.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What is the trial designed to test?
Who fits the planned study population?
What did earlier probiotic research find?
Which acne treatments have stronger support now?
What can you ask a dermatologist?

What is the trial designed to test?

The trial plans four parallel groups. Each group adds oral probiotic, topical secretome, both, or neither to standard acne therapy. Dual placebos cover both add-ons in the comparison group.

This design isolates the added effect of each product. It measures both clinical change and microbiome change. Readers should view it as a test of extra benefit, not a replacement for standard care.

Who fits the planned study population?

The study focuses on adolescents and adults with dermatologist-diagnosed mild-to-moderate facial acne vulgaris. The U.S. National Library of Medicine/PubMed record defines severity by Lehmann lesion counts, described in the PubMed trial record.

Mild disease means fewer than 20 comedones. Moderate disease means 20 to 100 comedones. A dermatologist can assess fit using steps such as:.

confirm facial acne vulgaris and grade severity
review current prescription and over-the-counter acne products
review recent antibiotics, retinoids, probiotics, and skin procedures

What did earlier probiotic research find?

Earlier controlled evidence is preliminary and strain-specific. A 104-patient randomized trial found Lactobacillus paracasei MSMC 39-1 lotion and 2.5% benzoyl peroxide both reduced inflammatory lesions and redness after four weeks, reported in the 2022 lotion trial report.

Results differ by strain and formula. A 2026 scoping review of 66 records in MDPI Cosmetics noted a five-trial Lactobacillus meta-analysis with 332 patients. That analysis found no significant lesion reduction versus placebo or benzoyl peroxide.

Which acne treatments have stronger support now?

Proven care remains the practical base while this protocol awaits results. The 2024 American Academy of Dermatology guidance strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, and selected combinations, detailed in the Academy guideline summary.

The same guidance supports isotretinoin for severe acne. Do not stop a working prescription to wait for probiotic or secretome data. Any change should go through the prescribing clinician.

What can you ask a dermatologist?

Bring your product list and acne history to the visit. Ask whether your grade of acne resembles the mild-to-moderate range being studied.

Ask how to keep proven treatment stable while tracking flares, irritation, and missed doses. Useful questions include:.

Does my current routine already include benzoyl peroxide, a retinoid, or another recommended option?
Could a probiotic lotion, supplement, or fermented product irritate my skin or interact with my treatment?
What signs should prompt a sooner follow-up, such as spreading pain, scarring, or worsening breakouts?
How long should we test my current plan before changing it?